Recent Finacing
Recent Raise
Caelum Biosciences is a clinical-stage biotech developing CAEL-101, a monoclonal antibody against insoluble light-chain amyloid fibrils to clear organ deposits, in Phase 1/2 development and overseeing manufacturing with Alexion.
